[M&A]

• Advised K Group on corporate governance restructuring.

• Advised on blind pool investment in facilities for the elderly and children.

• Advised HD Korea Shipbuilding & Offshore Engineering on the establishment of AMC Science and Asan Foundation's capital increase transaction; advised on technology licensing agreements between AMC Science and Asan Foundation/Ulsan University Industry-Academic Cooperation Foundation.

• Advised CSL Group on the integration of its three Korean entities and the spin-off of Seqirus.

• Advised MSD on the acquisition of Elanco's aquatic animal business division.

• Advised Daesang Wellife on the acquisition of FNDNet.

• Advised Dongwha Pharmaceutical on the asset acquisition of Celltrion Asia Pacific Pte. Ltd.'s OTC business division.

• Advised on the attempted acquisition of Synapix.

• Advised BioSolution on the acquisition of Helixmith.

• Advised Tecan Group AG on the acquisition of Greenmate Biotech's medical device/equipment business division.

• Advised BMS on the asset acquisition transaction from Orum Therapeutics.

• Advised on the attempted acquisition of Boryung Biopharma.

• Advised Huons Meditec on the transfer of the lithotripter business division from M.I. Tech.

• Advised on the attempted acquisition of Medit.

• Advised Demant Korea on the spin-off of its diagnostic equipment sales business division.

• Advised Boryung Pharmaceutical on the acquisition of assets related to original drugs

• Advised Kantar Group on the acquisition of its Health business division.

• Advised on the spin-off of MSD.

• Advised on the acquisition of Huons Biopharma.

• Advised on the attempted acquisition of Takeda's major product Asian business.

• Advised on the attempted acquisition of BMS's major product global business.

• Advised Baxter on the transfer of its bio business division.

• Advised Shire and Baxalta on stock purchase and merger for global integration.

• Advised Novartis on the acquisition of its Flu business division.

• Advised Alvogen on the transfer of its oral contraceptive business division.

• Advised Abbott on the acquisition of St. Jude Medical.

• Advised Pfizer on the transfer of its infusion therapy division.

• Advised global pharmaceutical companies and medical device companies on entering the Korean market, including entity establishment.

• Advised on the establishment of JVs for pharmaceutical/bio companies.

[Healthcare – Contracts & General Corporate]

• Provided comprehensive advice on entering the Korean market for global pharmaceutical/medical device companies.

• Provided corporate maintenance services for foreign-invested enterprises.

• Drafted, reviewed, and negotiated various global and domestic clinical trial agreements, including Clinical Trial Agreements, CRO Service Contracts, IISR Agreements, NIS Agreements, PMS Contracts, and research outsourcing contracts.

• Advised on contract drafting, review, negotiation, and transaction structures for License-in, License-out, and joint R&D agreements for pharmaceutical/bio and medical device companies.

• Drafted and negotiated various agreements related to the distribution and promotion of pharmaceuticals/medical devices, including supply and distribution agreements and promotion/co-promotion/co-marketing agreements; advised on contract termination and related disputes.

• Advised on transitional distribution service agreements and transitional manufacturing and supply agreements related to global/domestic healthcare deals, and other post-merger integration matters.

[Healthcare – Regulatory & Compliance]

• Advised pharmaceutical, biotechnology, and medical device companies on compliance due diligence, compliance system design, and the development of internal policies and standard operating procedures.

• Advised on CSO related issues.

• Advised on third-party due diligence for CSOs and wholesalers.

• Advised on MFDS/IRB approval for clinical trial plans, item licenses, business licenses, and the transfer/assignment of item/business licenses for pharmaceutical/bio and medical device companies.

• Advised on structural reviews and related regulations (Bioethics Act, Pharmaceutical Affairs Act/Medical Device Act, Personal Information Protection Act, etc.) for global clinical trials.

• Advised on national batch release approvals for vaccines, etc.

• Advised on the designation of essential national drugs.

• Advised on promotional activities, clinical trials/CRO, labeling/advertising, distribution, and import customs clearance for pharmaceuticals and medical devices.

• Provided compliance advice based on the Pharmaceutical Affairs Act, Medical Device Act, Medical Service Act, Anti-Graft Act, Fair Trade Act, and Industry Codes.

• Advised on the operation of patient support programs for pharmaceuticals.

• Advised on post-management matters such as re-evaluation of pharmaceuticals/medical devices.

• Advised on the Personal Information Protection Act regarding pharma, medical device businesses.

• Advised on licensing for cell therapies, genetic testing, and specimen testing entrusted institutions.

• Advised on Medical Service Act issues and unlicensed medical practices.

• Advised on requirements for establishing/operating facilities for the elderly and children.

• Advised on digital health matters.

• Represented clients in rebate investigations/investigations.

• Advised on responses to investigations, administrative dispositions and requests for official interpretations by the Ministry of Health and Welfare and the MFDS.

• Represented clients in recovery dispositions under the National Health Insurance Act and Senior Long-Term Care Insurance Act.

• Advised on licensing and other issues related to the establishment and operation of Robot Surgery Training Centers.

• Advised on dietary supplements, including recognition of functional raw materials.

• Advised on labeling, import customs clearance, and advertising for cosmetics, dietary supplements, and food products.

• Provided legislative consulting in the healthcare sector.

[Healthcare – Pricing & Reimbursement]

• Advised on new drug listings, expansion of health insurance coverage criteria, re-evaluation of appropriateness of health insurance benefits and defense against drug price reductions.

• Advised on increasing the upper limit of drug prices.

• Advised on the designation of Exit-Prevention Drugs (“퇴장방지의약품” in Korean) and related price increases.

• Advised on revisions to drug price announcements.

• Advised on health insurance reimbursement listing for therapeutic materials.

• Advised on drug price negotiations with the National Health Insurance Service.

• Advised on new medical technology assessment and procedure fee adjustments.

• Advised on designation as National Immunization Program (NIP) drugs.

[China Practice]

• Advisory on the establishment of a joint venture in China for Dasan Pharmaceutical.

• Advisory on labeling and advertising of medical devices for the Chinese affiliate.

• Pharmaceutical Advertising (Korea Chapter): International Comparative Legal Guide (Co-author, 2021-2025)
• Medicinal Product Regulation and Product Liability (Korea Chapter): A Global Guide From Practical Law (Co-author, 2021, 2022, Thomson Reuters; 2023-2025)
• The Healthcare Law Review (Korea Chapter) (Co-author, 2021-2025)
• Life Sciences (Korea Chapter): Lexology Getting The Deal Through (Co-author, 2020, 2021)
• Pharma & Medical Device Regulation (Korea Chapter): Lexology Getting The Deal Through (Co-author, 2022-2025)